Custom Search


Tuesday 01 March 2005

Ziprasidone as an augmenting agent in the treatment of anxiety-spectrum disorders.

By: Crane DL.

CNS Spectr 2005 Mar;10(3):176-9

Anxiety disorders are currently one of the most common health concerns in the United States. Overall, they are the single largest cost to the healthcare system. They are also underdiagnosed and undertreated. Selective serotonin reuptake inhibitors and benzodiazepines appear to be the most common pharmacologic treatment approaches. Unfortunately, not all patients respond to these treatments. Many augmentation strategies have been tried in the past with varying levels of success or safety. This article describes a safe and highly effective augmentation technique in patients suffering from some of the most serious and debilitating forms of anxiety disorders, namely obsessive-compulsive disorder and panic disorder.

Use of this site is subject to the following terms of use